In the future, China Education Company, China Medical Company and China Pension Company are destined to lose money. This is determined by the nature of the three companies.
But China Pharmaceutical Group is different. Zhao Yi is very optimistic about this company's future earning power.
In the future, this company will operate entirely in accordance with marketization. In other words, the pharmaceutical equipment it provides to Chinese medical companies will be supplied at market prices.
In this case, most of the annual financial expenditure allocated to the medical system will still go into the pockets of Chinese pharmaceutical companies, and the rest will be used to pay the salaries of medical staff.
This revenue alone is measured in hundreds of billions of yuan every year, and will even reach the level of trillions of yuan in the future. This amount of revenue is enough for pharmaceutical companies to survive well.
Of course, this is actually a relationship of left hand and right hand. If China Medical Company suffers losses and Zhao Yi still has to make up for it himself, then the money may still come from China Medical Company.
This is why Zhao Yi wants to increase the cure rate of Chinese Medical Company as much as possible, and even does not hesitate to personally teach Chinese Medical Company related medical plans, in order to reduce the losses of Chinese Medical Company.
If the two companies operate well and can cooperate closely, then generally speaking, there is still some money to be made, and it will not be a loss-making transaction.
However, the entire welfare system may still be in a state of loss as a whole, which means that relying solely on their internal circulation cannot avoid losses, at least in the short term.
Therefore, in addition to operating the domestic pharmaceutical market, Chinese pharmaceutical companies also need to expand outward and earn funds from other countries and regions to increase their income and make up for the overall shortfall in the domestic welfare system.
Of course, Chinese medical companies do not provide free treatment for all diseases, but only treat diseases that are harmful to the human body, such as minor colds and fevers, major tumors, cerebral palsy, etc.
However, Chinese medical companies do not provide free treatment for diseases that do not affect the overall health of the human body, such as plastic surgery, short brother, myopia, dental disease, etc. Patients need to pay for the treatment themselves or purchase relevant commercial insurance.
This will also be a major source of income for Chinese medical companies in the future. Although the charges per case are not very high, it cannot support the strong demand for treatment in this area, and the market size is still very large.
If these businesses are expanded to overseas markets and are unanimously recognized by overseas patients, then the funds earned from overseas markets alone can make up for the domestic losses of Chinese medical companies.
The same is true for Chinese pharmaceutical companies. The specific drugs they research are sustainable for patients around the world, especially those diseases that are currently difficult to treat or have no cure. The profits they earn will be even greater. very horrible.
Take HIV as an example. I believe that as long as there is a possibility of cure, patients will not mind spending large sums of money for treatment, just like those with cancer. After all, money is nothing compared to life.
Chinese pharmaceutical companies are developing specific drugs or treatment plans for these diseases that have plagued mankind for a long time, which can effectively treat these diseases.
That's why Zhao Yicai said that in the future, the annual operating income of Chinese pharmaceutical companies will reach a terrifying trillion level, or even ten trillion levels. This is the confidence that Zhao Yi has brought to Chinese pharmaceutical companies.
But when this giant in the pharmaceutical industry grows up, it is estimated that pharmaceutical companies all over the world will suffer disaster, either going bankrupt or researching some insignificant medical equipment, such as glucose, physiological saline, etc.
Moreover, even if Chinese pharmaceutical companies achieve a market size of more than ten trillion yuan, they do not have to worry about antitrust investigations by other countries.
The reason is simple. Life and health are the aspirations and aspirations of all mankind. If Chinese pharmaceutical companies are banned or increase tariffs on drugs, the worst possible outcome is that they will not be sold to those countries, or the prices of their products will be increased.
In the end, it is the citizens of these countries who bear the losses. There is no loss at all to the Chinese medical companies. Even because of the ban on related drugs, their citizens can come to Chinese medical companies for treatment and earn a second wave of profits.
This is also the reason why Zhao Yiyi has no fear of Chinese pharmaceutical companies, because the medical and pharmaceutical industry is different from other industries and has very special industry attributes, and it is an area where the strong is king.
Of course, if Chinese pharmaceutical companies really achieve an absolute monopoly in the global pharmaceutical market, those countries can also declare support for generic drugs and ignore pharmaceutical patents like India.
To be honest, such a move can really cause some trouble for Chinese pharmaceutical companies. At least drugs that are easy to copy will not make profits.
However, many drug formulas of Chinese pharmaceutical companies are quite complex, and many drugs have extremely high technological content and cannot be manufactured by ordinary companies.
Knowing the formula is one thing, whether it can be produced is one thing, and the quality of the production is another. As for these drugs that cannot be copied, Chinese pharmaceutical companies can sell them at high prices to make up for the losses of other drugs that are copied. .
Just doing this is very inhumane. After all, medicine is still about saving people, and making profits is just a matter of incident. Therefore, in order to avoid this situation, Zhao Yi still allows Chinese pharmaceutical companies to earn appropriate profits and don't force them too much. ruthless.
Therefore, when setting the price of pharmaceutical products in the future, it is necessary to take a comprehensive consideration with reference to the number of global patients and production costs.
For diseases that have a small number of patients globally but for which there are no specific drugs, the price will definitely be much higher. For those products with a large patient base and no specific drugs, the price can be reduced appropriately.
Strive to allow more patients to use these drugs, and Chinese pharmaceutical companies can also receive satisfactory remuneration.
For those diseases that already have high cure rates, Chinese pharmaceutical companies do not mind lowering the price of medicines and seizing part or even all of the market in this area.
A company that does not want to pursue a monopoly position is not a good company. Therefore, Chinese pharmaceutical companies are determined to be a pharmaceutical company with an industry monopoly.
Now Chinese pharmaceutical companies are building production bases across the country to prepare for the upcoming takeover of the domestic medical industry.
By then, production bases across the country will be activated to continuously produce the drugs and equipment needed by Chinese medical companies.
Only after meeting domestic demand will Chinese pharmaceutical companies consider exploring the international market. Of course, it is estimated that the market is not that easy to enter. Many drugs entering other countries need to obtain drug approval from the country where they are located.
Therefore, this matter will not be accomplished overnight. It is even possible that the approval time for some drugs can be as long as ten years. It can only be done slowly. Anyway, Chinese pharmaceutical companies are still very confident in their products.
Due to large-scale investment in infrastructure and R&D, Zhao Yi has injected 100 billion yuan into Chinese pharmaceutical companies. He hopes that they can develop drugs to solve most diseases within a year and complete the Zhao Yi government's plan. promise.
In order to achieve this goal, Zhao Yi personally held relevant talks with the government and required all domestic experts and scholars with medical research level to rush to China Pharmaceutical Company to help. If they are willing to join the company, relevant units must not obstruct them.
Of course, doing so has harmed the interests of many domestic pharmaceutical companies, so Zhao Yi has also made a relevant commitment, that is, Chinese pharmaceutical companies will not be involved in any pharmaceutical products they are currently involved in, at least not domestically.
Doing so protects the interests of these companies. You must know that Chinese medical companies contract the entire domestic medical care. If they are offended, Chinese medical companies have no need to use their products.
At that time, they will have no choice but to close their doors.
Therefore, in order to ensure their financial resources, they had no choice but to agree to Zhao Yi's request and send all the R&D personnel with R&D capabilities in their company to Chinese pharmaceutical companies.
The reason why Zhao Yi is so tough is related to the contract signed by the government. For the government, as long as the Chinese medical company can provide the promised service quality, it will not care about the specific operations of the Chinese medical company.
In other words, the government only needs to look at the effectiveness of Chinese medical companies in operating the entire domestic medical system, and does not care how it is achieved. Only when the quality of medical services is inconsistent with their promises will they intervene to investigate or hold them accountable.
In this way, the government departments will save a lot of trouble, and Chinese medical companies will also have higher autonomy. But if they do this, all other domestic pharmaceutical companies will suffer.
They had been unable to do anything about this before and had written to the government, but there was no good solution. Compared with the normal operation of the entire domestic medical system, their interests were not very big.
This time, Zhao Yi proposed the secondment of R&D personnel, which gave them the opportunity to make demands. Zhao Yi also agreed to their requests to avoid unnecessary troubles.
In fact, the more important thing is that Zhao Yi doesn't like their pharmaceutical products. They are all drugs for treating common diseases. They have very low technical content and will not be very profitable.
In addition, the entire domestic medical industry is now controlled by Chinese medical companies, which have greater bargaining power. Their profits may be further compressed, and they are operating at a low profit.
Of course, Chinese medical companies will not go too far and will still leave them with reasonable profits so that their companies can continue to operate and contribute to my country's medical industry. Don't even think about huge profits.
The main pharmaceutical research direction of Chinese medical companies is drugs whose products cannot cure diseases, or domestic drugs with poor therapeutic effects.
These drugs are not only technically difficult, but some also have gaps in the market, allowing Chinese pharmaceutical companies to earn more profits without causing a backlash from domestic pharmaceutical companies.
As for international medical colleagues, Zhao Yi doesn't care much. If there is no conflict of interest, it's fine. If there is a conflict of interest, just do it. Is a person with cheating still afraid of them
Through this secondment of R&D personnel, the anxiety of domestic pharmaceutical companies has been solved, and this headache has also been solved for relevant government departments. Everyone is happy.
It's just that the international pharmaceutical giants are still in the dark, completely unaware that an international monopoly pharmaceutical giant is quietly taking shape, and the future will be a nightmare they will never get rid of. (End of chapter)